Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Puma Biotechnology (PBYI)

Puma Biotechnology (PBYI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 264,656
  • Shares Outstanding, K 48,207
  • Annual Sales, $ 235,640 K
  • Annual Income, $ 21,590 K
  • 60-Month Beta 1.28
  • Price/Sales 1.13
  • Price/Cash Flow 8.37
  • Price/Book 5.19
Trade PBYI with:

Options Overview Details

View History
  • Implied Volatility 103.59% ( -4.87%)
  • Historical Volatility 79.62%
  • IV Percentile 51%
  • IV Rank 19.76%
  • IV High 503.26% on 11/03/23
  • IV Low 5.17% on 10/17/23
  • Put/Call Vol Ratio 0.13
  • Today's Volume 43
  • Volume Avg (30-Day) 507
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 12,376
  • Open Int (30-Day) 10,386

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.21
  • Low Estimate -0.22
  • Prior Year 0.03
  • Growth Rate Est. (year over year) -833.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.14 +27.29%
on 03/19/24
6.05 -12.96%
on 04/09/24
-0.08 (-1.50%)
since 03/12/24
3-Month
4.14 +27.29%
on 03/19/24
7.73 -31.82%
on 02/15/24
+0.32 (+6.57%)
since 01/12/24
52-Week
2.13 +147.42%
on 10/25/23
7.73 -31.82%
on 02/15/24
+2.36 (+81.10%)
since 04/12/23

Most Recent Stories

More News
Puma Biotech: Q4 Earnings Snapshot

Puma Biotech: Q4 Earnings Snapshot

PBYI : 5.27 (-4.01%)
Puma Biotech: Q3 Earnings Snapshot

Puma Biotech: Q3 Earnings Snapshot

PBYI : 5.27 (-4.01%)
Puma Biotech: Q2 Earnings Snapshot

Puma Biotech: Q2 Earnings Snapshot

PBYI : 5.27 (-4.01%)
Five Top Companies Fighting for the Treatment of Metastatic Breast Cancer

A significant medical breakthrough is needed in the fight against metastatic breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of...

LLY : 751.64 (-1.05%)
PBYI : 5.27 (-4.01%)
GILD : 68.07 (-0.84%)
IMGN : 31.23 (unch)
BCTX : 2.49 (-7.09%)
BCT.TO : 3.40 (-8.36%)
There are Positive Developments in the Treatment of Metastatic Breast Cancer

A significant medical breakthrough is desperately needed in the fight against metastatic breast cancer. As it stands right now, metastatic breast cancer has no cure and has proven resistant to many cancer...

LLY : 751.64 (-1.05%)
PBYI : 5.27 (-4.01%)
GILD : 68.07 (-0.84%)
IMGN : 31.23 (unch)
BCTX : 2.49 (-7.09%)
BCT.TO : 3.40 (-8.36%)
Five Impressive Metastatic Cancer Treatment Stocks to Own Today

A significant medical breakthrough is desperately needed in the fight against breast cancer. At the moment, according to the American Cancer Society, more than 3.1 million women in the United States alone...

LLY : 751.64 (-1.05%)
PBYI : 5.27 (-4.01%)
GILD : 68.07 (-0.84%)
IMGN : 31.23 (unch)
BCTX : 2.49 (-7.09%)
BCT.TO : 3.40 (-8.36%)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...

PBYI : 5.27 (-4.01%)
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y

Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.

PBYI : 5.27 (-4.01%)
RCUS : 16.58 (-4.11%)
ALLO : 3.80 (-4.76%)
OCUP : 1.8400 (+2.79%)
Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 550% and 6.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

PBYI : 5.27 (-4.01%)
LCTX : 1.3000 (-7.80%)
Puma Biotech: Q1 Earnings Snapshot

Puma Biotech: Q1 Earnings Snapshot

PBYI : 5.27 (-4.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) was launched in the United Statesfor the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche's Herceptin-based adjuvant therapy. The drug was also...

See More

Key Turning Points

3rd Resistance Point 5.76
2nd Resistance Point 5.64
1st Resistance Point 5.46
Last Price 5.27
1st Support Level 5.15
2nd Support Level 5.03
3rd Support Level 4.84

See More

52-Week High 7.73
Fibonacci 61.8% 5.59
Last Price 5.27
Fibonacci 50% 4.93
Fibonacci 38.2% 4.27
52-Week Low 2.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar